Carcinogenicity Risk Assessment Reports & the Weight of Evidence (WoE) Approach
We have recently launched a new product, the CRA reports, that follows the Weight of Evidence (WoE) approach presented in the ICH S1B(R1) addendum that was recently approved by the FDA and EMA. The reports present a comprehensive assessment of the data relevant to carcinogenic potential available from public sources and from relevant drug development studies.
Our CRA reports contain information on:
-Target biology
-Cancer models
-Relevant safety findings-preclinical and clinical safety findings on class effects
-Carcinogenic potential-summary according to ICH S1B(R1)
Download
Carcinogenicity Risk Assessment Brochure
Learn more in our Carcinogenicity Risk Assessment Webinar Series:
Please click on one of our webinars below to learn more about our Carcinogenicity Risk Assessment Reports.
“Outsourcing our Target Safety Assessment Reports to Metisox, for the past 5 years, has helped speed up our toxicology investigations as well as provide insightful mitigation plans that we were unable to deduce from our internal resources”
– Study Director, Toxicology
Carcinogenicity Risk Assessment Reports & the Weight of Evidence (WoE) Approach Webinar on demand
Bulk discount offer – To learn more about our CRA Reports and/or request information on bulk discount options, please provide your details below:
Are you looking to increase the efficiency and knowledge base of your internal TSA Report writing?
SysWiz Database Subscription
Access to Metisox’s proprietary SysWiz database
Training sessions provided as standard
Individual(s) license or site-wide license available
Utilise cutting edge artificial intelligence tools
Bespoke database modules available upon request
2023 Discounts currently available
Click here for more information
Precision Insights 2023 Software
Early Access to Metisox’s proprietary Precision Insights Software
Full integration into your bioinformatics pipeline
Bespoke development of artificial intelligence tools
Multiomics data platform
Combine analysis of historical and new data sets
2023 Discounts currently available
Click here for more information